Yttrium-90 microspheres (TheraSphere®) treatment of unresectable hepatocellular carcinoma: Downstaging to resection, RFA and bridge to transplantation

Kulik, Laura; Atassi, Bassel; Holsbeeck, Lodewijk van; Souman, Tameem; Lewandowski, Robert J.; Mulcahy, Mary F.; Hunter, Russell; Nemcek, Albert A.; Abécassis, Michaël; Haines, Kenneth; Salem, Riad

doi:10.1002/jso.20609

Cited by 313 publications

(201 citation statements)

References 47 publications

Supporting

Mentioning

190

Contrasting

Unclassified

Order By: Relevance

“…Moreover, Y90-RE begins to be proposed by different authors as a treatment of choice in patients with (9). For this reason Y90-RE could be considered an effective tool for the downstaging strategy to LT in selected patients (10).…”

Section: Discussionmentioning

confidence: 99%

Hepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation

Sandri

Ettorre

Colasanti

et al. 2017

Hepatobiliary Surg. Nutr.

View full text Add to dashboard Cite

Background: Yttrium-90 microspheres radioembolization (Y90-RE) has shown to be an effective and safe treatment of primary liver tumors. According to the staging system of the Barcelona Clinic Liver Cancer (BCLC), patients with macrovascular invasion are staged as BCLC-C. This paper comprises a presentation of the results following application of the procedure.Methods: From January 2002 to December 2015, 367 patients were transplanted at the San Camillo Hospital Center. One hundred and forty-three patients were transplanted for hepatocellular carcinoma (HCC) and in 22 cases patients were treated with Y90-RE before liver transplantation (LT), of them 4 with macrovascular invasion were included in this study. Results:The four patients had a complete response for the thrombosis, and were included in the waiting list within the Milan criteria. Means interval time between Y90-RE and LT was 15.86 months. No patient death was observed at Y90-RE procedure or at LT. We obtain a free-survival of 39.1 (range, 6-76) months.In all four cases the complete thrombosis regression was observed. Conclusions:We reported a short series of patients transplanted after Y90-RE in patients with BCLC stage C. In our experience we achieved acceptable overall and disease-free survival. Eventually, Y90-RE seems to have a place in the downstaging strategy for LT candidates.

show abstract

Section: Discussionmentioning

confidence: 99%

Hepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation

Sandri

Ettorre

Colasanti

et al. 2017

Hepatobiliary Surg. Nutr.

View full text Add to dashboard Cite

show abstract

“…In 14 articles clinical data were presented on tumor response and survival for 425 patients with HCC who had received 90 Y-RE [11,18,24,[30][31][32][33][34][35][36][37][38][39][40]. Twelve studies presented data of tumor response for a total of 318 patients.…”

Section: Hepatocellular Carcinomamentioning

confidence: 99%

Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis

et al. 2008

View full text Add to dashboard Cite

“…A proof-of-concept study used rfa to downsize hccs to T2 from T3 in 19 of 34 patients, achieving a 1-year survival of 84% and a 3-year survival of 27% 25 . Radiofrequency ablation has also been directly compared with tace for success of downsizing, with 43 patients and a comparable median tumour diameter of 5.6 cm in each group.…”

Section: Discussionmentioning

confidence: 99%

Magnitude of Change in Alpha-Fetoprotein in Response to Transarterial Chemoembolization Predicts Survival in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma

et al. 2013

View full text Add to dashboard Cite

show abstract

Yttrium-90 microspheres (TheraSphere®) treatment of unresectable hepatocellular carcinoma: Downstaging to resection, RFA and bridge to transplantation

Abstract: These data suggest that intra-arterial (90)Y microspheres can be used as a bridge to transplantation, surgical resection, or RFA.

Cited by 313 publications

References 47 publications

Hepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation

Hepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation

Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis

Magnitude of Change in Alpha-Fetoprotein in Response to Transarterial Chemoembolization Predicts Survival in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma

Contact Info

Product

Resources

About